Abstract
a Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
